Synergy CHC Corp. (SNYR) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Synergy CHC Corp. is a consumer health care company focused on nutraceuticals, primarily through its brands FOCUSfactor and Flat Tummy. The company operates as a non-accelerated filer and smaller reporting company. This summary covers the unaudited quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $8,134,996 | $16,305,530 | $8,024,840 | $17,436,703 |
| Gross Profit | $6,238,605 (77%) | $12,402,626 (76%) | $5,575,950 (69%) | $12,350,674 (71%) |
| Net Income | $1,473,237 | $2,349,501 | $655,186 | $1,235,716 |
| EPS (Diluted) | $0.17 | $0.27 | $0.09 | $0.17 |
| Cash & Equivalents | $1,458,561 (June 30, 2025) Restricted Cash: $100,000 |
|||
| Total Debt (Net) | ||||
| Working Capital | $12,383,132 (Surplus) |
Material Changes vs. Prior Period
- Revenue Composition: While total revenue remained relatively flat quarter-over-quarter, the mix shifted significantly. Product sales decreased by 16% ($6.7M vs $8.0M) due to a non-recurring sell-in in 2024. This was offset by $1.4M in new License Revenue, which was absent in the prior year.
- Profitability: Net income increased 125% quarter-over-quarter ($1.47M vs $0.66M). This surge is primarily driven by a $2.15M gain on the settlement of notes payable, rather than core operational improvements.
- Debt Restructuring: The company significantly altered its capital structure. It secured a new $17.5M term loan in May 2025 to refinance existing obligations. Consequently, long-term debt increased to ~$25M, while short-term shareholder notes were largely extinguished via cash repayment and equity conversion.
- Operating Expenses: General and Administrative (G&A) expenses rose 68% quarter-over-quarter ($1.52M vs $0.90M), attributed to public market compliance costs. Selling and marketing expenses remained stable.
Outlook, Risks, and Unusual Items
- Unusual Items: The financial results are heavily influenced by non-cash and one-time items, specifically the $2.15M gain on debt settlement and significant interest expense ($2.1M for Q2) related to new financing and amortization of debt discounts.
- Liquidity & Going Concern: Management has alleviated substantial doubt regarding the company's ability to continue as a going concern, citing a working capital surplus of $12.4M and successful debt refinancing. However, the company maintains an accumulated deficit of $41.8M.
- Debt Covenants: The new $17.5M credit agreement with ACP Agency, LLC imposes strict covenants, including a maximum consolidated senior net leverage ratio (starting at 3.25:1) and a fixed charge coverage ratio of 1.20:1. Failure to meet these could trigger default.
- Controls and Procedures: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025.
- Concentration Risk: Revenue is highly concentrated; three customers accounted for approximately 82% of net revenue in Q2 2025. Similarly, two customers accounted for 84% of trade accounts receivable.
Investor Verification Checklist
- Debt Sustainability: Verify the company's ability to meet the new leverage and coverage covenants under the $17.5M ACP Agency loan, given the high interest rate (SOFR + 8.5%).
- Revenue Quality: Assess the sustainability of the $1.4M license revenue and the reasons for the decline in core nutraceutical product sales.
- Related Party Transactions: Review the $4.4M loan receivable from a related party (controlled by the CEO) and the terms of its repayment due December 31, 2025.
- Internal Controls: Investigate the specific deficiencies leading to the conclusion that disclosure controls were ineffective.
- Cash Flow vs. Net Income: Note that despite reporting net income, the company used $0.9M in cash from operating activities YTD, driven by increases in receivables and inventory.